Clinical trial · Observational
Evaluation of Cardiotoxic Effects of Bortezomib
Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here. The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxins | — | UNRESOLVED | — |
| Heart Failure, Systolic | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib | Drug | Bortezomib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Multiple Myeloma, Bortezomib
- interventionNames
- Drug: Bortezomib
Primary outcomes (1)
- measure
- Global longitudinal strain by echocardiography
- timeFrame
- 6 months
Secondary outcomes (6)
- measure
- Amount of late gadolinium enhancement by cardiac MRI
- timeFrame
- 6 months
- measure
- High-sensitivity troponin T
- timeFrame
- 6 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of multiple myeloma * have a treatment plan involving greater than 4 cycles of bortezomib-based chemotherapy Exclusion Criteria: * pre-existing history of left ventricular systolic dysfunction * congestive heart failure * coronary artery disease * significant valvular heart disease * cardiac arrhythmias * estimated glomerular filtration rate \<30 mL/min/1.73m2
References
Publications (0)
Data not yet available